TcpC inhibits toll-like receptor signaling pathway by serving as an E3 ubiquitin ligase that promotes degradation of myeloid differentiation factor 88.
Jia-Qi FangQian OuJun PanJie FangDa-Yong ZhangMiao-Qi QiuYue-Qi LiXiao-Hui WangXue-Yu YangZhe ChiWei GaoJun-Ping GuoThomas MiethkeJian-Ping PanPublished in: PLoS pathogens (2021)
TcpC is a virulence factor of uropathogenic E. coli (UPEC). It was found that TIR domain of TcpC impedes TLR signaling by direct association with MyD88. It has been a long-standing question whether bacterial pathogens have evolved a mechanism to manipulate MyD88 degradation by ubiquitin-proteasome pathway. Here, we show that TcpC is a MyD88-targeted E3 ubiquitin ligase. Kidney macrophages from mice with pyelonephritis induced by TcpC-secreting UPEC showed significantly decreased MyD88 protein levels. Recombinant TcpC (rTcpC) dose-dependently inhibited protein but not mRNA levels of MyD88 in macrophages. Moreover, rTcpC significantly promoted MyD88 ubiquitination and accumulation in proteasomes in macrophages. Cys12 and Trp106 in TcpC are crucial amino acids in maintaining its E3 activity. Therefore, TcpC blocks TLR signaling pathway by degradation of MyD88 through ubiquitin-proteasome system. Our findings provide not only a novel biochemical mechanism underlying TcpC-medicated immune evasion, but also the first example that bacterial pathogens inhibit MyD88-mediated signaling pathway by virulence factors that function as E3 ubiquitin ligase.
Keyphrases
- toll like receptor
- signaling pathway
- nuclear factor
- inflammatory response
- escherichia coli
- immune response
- amino acid
- pi k akt
- pseudomonas aeruginosa
- epithelial mesenchymal transition
- biofilm formation
- small molecule
- dendritic cells
- drug delivery
- bone marrow
- gram negative
- type diabetes
- metabolic syndrome
- oxidative stress
- multidrug resistant